Please ensure Javascript is enabled for purposes of website accessibility

Why Geron Corporation Stock Is Heating Up

By George Budwell - May 23, 2018 at 1:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron's stock is blasting higher this week, but the exact reason isn't clear.

What happened

Shares of the clinical-stage biotech Geron Corporation (GERN 7.74%) are up by double digits for the second day in a row on no apparent news. What's going on?

While the company hasn't released any material news this week to explain this sudden move higher, Geron's stock might be responding to two recent developments:

  1. Congress passed a so-called "right-to-try" bill today, which could clear the way for terminally ill patients to experiment with the company's first-in-class telomerase inhibitor imetelstat as a drug of last resort.
  2. Geron and its partner Johnson & Johnson (JNJ 1.13%) announced last Thursday that imetelstat's ongoing lower risk myelodysplastic syndromes (MDS) study was selected for an oral presentation at the 23rd Congress of the European Hematology Association in June. 
A sickly man in bed surrounded by his adult woman and man.

Image source: Getty Images.

Geron's stock is presently up by 13%, as of 11:44 a.m. EDT. 

So what

Prior to this week's rally, Geron's stock was having trouble finding a bottom after the company announced that it decided to raise around $50 million in capital during the last quarter in the event J&J decides to nix their ongoing blood cancer collaboration. With this upcoming oral presentation now on the schedule, however, investors are apparently more confident that J&J is going to stick around.  

Now what

The key issue here is that this forthcoming MDS presentation should include a meaty update regarding imetelstat's progress in the expanded subset of patients who are naive to lenalidomide and hypomethylating treatment and lack the del(5q) mutation. And as this is an oral presentation and not simply a poster, these data are probably going to be impressive. Oral conference presentations, after all, are typically reserved for substantial developments.  

So while this right-to-try news is a positive, the most important event to keep an eye on is imetelstat's MDS update at next month's European Hematology Association meeting. Until then, Geron's stock appears set to continue edging higher in anticipation of this next clinical progress report.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
GERN
$1.67 (7.74%) $0.12
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.52 (1.13%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.